Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC Homeopathic Disclaimer Policy Should Prompt FDA Changes – Advocacy Group

Executive Summary

Center for Inquiry reiterates its criticism of homeopathy and calls on FDA to step up vetting of US-marketed homeopathic products.


Related Content

Teething Tablets, Toothpaste Recalls: Consumer Health Industry News Roundup
Congress Recommends Public Rulemaking In Puerto Rico: Health & Wellness Industry News Roundup
Burt's Bees Protein Shakes, Bulletproof Fatwater: Health & Wellness New Products Roundup
OTC Homeopathic Labels Must Include Scientific Disclaimers – FTC
FDA Examination Of Homeopathic Regulation Looks Beyond Safety History
Science-Based Evaluation Advocates Want Tighter Homeopathic Oversight
Inspection, AERs Prompt Hyland's Teething Tablets Recall





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts